Thromboembolic risk of intravenous and subcutaneous immunoglobulin treatment for neuroinflammatory diseases
SCIg is at least equivalent in thromboembolic risk to IVIg and may be safer for patients with existing vascular risk factors.
Authors
- Susan M. Cooper (ORCID: https://orcid.org/0009-0008-1227-8540)
- H. Jeff Smith (ORCID: https://orcid.org/0000-0002-8054-7721)
- Thomas R. Rogers (ORCID: https://orcid.org/0000-0003-4336-7729)
- David Gosal
- Ryan Keh (ORCID: https://orcid.org/0000-0001-6434-9496)
- Laura M. White
Institutions
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- Salford Royal Hospital (GB)
- Lancaster University (GB)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1136/jnnp-2025-337097
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00